1. Home
  2. ASAN vs KNSA Comparison

ASAN vs KNSA Comparison

Compare ASAN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$5.43

Market Cap

3.4B

Sector

Technology

ML Signal

HOLD

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$46.96

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASAN
KNSA
Founded
2008
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.5B
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
ASAN
KNSA
Price
$5.43
$46.96
Analyst Decision
Buy
Strong Buy
Analyst Count
14
7
Target Price
$12.62
$55.29
AVG Volume (30 Days)
5.5M
565.9K
Earning Date
03-02-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
27.93
225.00
EPS
N/A
0.75
Revenue
$790,806,000.00
$677,564,000.00
Revenue This Year
$10.19
$38.01
Revenue Next Year
$7.91
$17.42
P/E Ratio
N/A
$63.27
Revenue Growth
9.25
60.09
52 Week Low
$5.55
$19.42
52 Week High
$19.00
$50.03

Technical Indicators

Market Signals
Indicator
ASAN
KNSA
Relative Strength Index (RSI) 23.01 51.17
Support Level N/A $39.96
Resistance Level $6.67 $48.14
Average True Range (ATR) 0.37 1.83
MACD 0.00 -0.03
Stochastic Oscillator 1.13 45.20

Price Performance

Historical Comparison
ASAN
KNSA

About ASAN Asana Inc.

Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: